We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NPB:NYSENorthpointe Bancshares, Inc. Analysis

Data as of 2026-05-28 - not real-time

$17.30

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Northpointe Bancshares (NPB) trades at $17.30, comfortably above its identified support of $16.87 and below the near‑term resistance of $17.94. The stock sits slightly under its 20‑day SMA (17.41) and 50‑day SMA (17.60), indicating a modest short‑term price lag, while the 200‑day SMA (17.42) is almost flat with the current level, suggesting a neutral longer‑term trend. Technical signals are mixed: the RSI of 46.6 points to a neutral momentum, but the MACD histogram is positive and the MACD line is above its signal, providing a bullish tilt. Volatility is elevated at 31% over the past 30 days and beta is 1.06, implying the stock moves slightly more than the market and could experience sharper swings.
Fundamentally, NPB appears attractively priced. A trailing P/E of 7.7 versus an industry average of 16.5 signals a substantial valuation discount, while the price‑to‑book of 1.01 aligns closely with book value. Revenue growth is robust at 28% YoY, operating margin stands at 46% and ROE at 15%, underscoring strong profitability. The dividend yield of 0.58% is modest but the payout ratio of just 4.5% makes the dividend highly sustainable. Analyst consensus targets around $21 imply roughly a 22% upside, and the market sentiment index shows “Extreme Greed,” indicating bullish investor appetite.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near technical support with bullish MACD signal
  • High short‑term volatility and modest volume
  • Valuation discount provides downside cushion

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and high operating margins
  • Undervalued multiples relative to industry peers
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Solid ROE and consistent profitability
  • Long‑run upside potential toward analyst price targets
  • Resilient balance sheet despite elevated debt levels

Key Metrics & Analysis

Financial Health

Revenue Growth27.90%
Profit Margin35.11%
P/E Ratio7.7
ROE15.01%
ROA1.33%
P/B Ratio1.0
Op. Cash Flow$27.6M
Industry P/E16.5

Technical Analysis

TrendNeutral
RSI46.6
Support$16.87
Resistance$17.94
MA 20$17.41
MA 50$17.60
MA 200$17.42
MACDBullish
VolumeStable
Fear & Greed Index92.91

Valuation

Target Price$21.08
Upside/Downside21.87%
GradeUndervalued
TypeBlend
Dividend Yield0.58%

Risk Assessment

Beta1.06
Volatility31.39%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.